ASTA Comments to FDA on Voluntary Sesame Labeling Guidance
ASTA issued comments to the Food and Drug Administration (FDA) in February 2021 on the Voluntary Disclosure of Sesame as an Allergen: Guidance for Industry. Comments outline inconsistencies and confusion arising from the guidance, including that FDA policy already provides that sesame should not be labeled under the generic declaration of spices. ASTA requests that FDA revoke the voluntary guidance due to the legislative process and the FASTER Act.
Membership Required
A valid ASTA membership is required to access this page. Please use the form below to log in with your ASTA member account.
Log in
Not a member yet? Click here to learn about joining ASTA today.
Related Resources
Coalition Comments to FDA Requesting Sesame Labeling Compliance Date Clarification
ASTA signed onto FBIA coalition comments to the Food and Drug Administration (FDA) in April 2022, requesting that the FDA clarify that the compliance date under the Food Allergy Safety, Treatment, Education, and Research Act (FASTER) means that food products containing sesame must be labeled with a sesame allergen statement on or after January 1, 2021 and that products labeled before that do not need to be in compliance with the FASTER Act.
Multi-Industry Letter to FDA on Possible Use of 3rd Party Audit Data
ASTA signed onto a letter from multiple industries to FDA's Associate Commissioner Michael Rogers in September 2024 requesting a meeting to discuss the potential use of 3rd party food safety audit data as part of the Agency's inspection strategy.
